Kraig Biocraft Laboratories Accelerates Operations into Two Rearing Centers in One of Southeast Asia's Premier Silk-Producing Regions
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has announced the successful transition of its production operations to two new rearing centers in a major Southeast Asian silk-producing region. The new facilities, operated by the Company's subsidiary Prodigy Silk, have already surpassed all previous years of production combined since the first center opened in early 2024.
The modern rearing centers combine advanced biotechnology with the region's established sericulture expertise, favorable climate, and infrastructure. The Company is completing the transfer of equipment from its original pilot facility, with completion expected by the end of August 2025. This strategic move represents a significant expansion milestone for Kraig Labs in commercializing spider silk technology.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader nella tecnologia della seta di ragno, ha annunciato il completamento della transizione delle attività produttive in due nuovi centri di allevamento in una importante regione produttrice di seta del Sud-Est asiatico. I nuovi impianti, gestiti dalla controllata Prodigy Silk, hanno già superato la produzione cumulata di tutti gli anni precedenti dall’apertura del primo centro all’inizio del 2024.
I moderni centri uniscono biotecnologie avanzate all’esperienza locale nella sericoltura, approfittando del clima favorevole e delle infrastrutture. L’azienda sta portando a termine il trasferimento delle attrezzature dal sito pilota originale, con conclusione prevista entro la fine di agosto 2025. Questa mossa strategica segna una tappa importante nell’espansione commerciale di Kraig Labs nella tecnologia della seta di ragno.
Kraig Biocraft Laboratories (OTCQB: KBLB), líder en tecnología de seda de araña, ha anunciado la exitosa transición de su producción a dos nuevos centros de cría en una importante región productora de seda del Sudeste Asiático. Las nuevas instalaciones, operadas por la filial Prodigy Silk, ya han superado la producción acumulada de todos los años anteriores desde que se abrió el primer centro a principios de 2024.
Los modernos centros combinan biotecnología avanzada con la consolidada experiencia sericícola de la región, su clima favorable e infraestructuras. La compañía está completando el traslado del equipo desde la instalación piloto original, con finalización prevista para fines de agosto de 2025. Este movimiento estratégico representa un hito relevante en la expansión comercial de Kraig Labs en la tecnología de la seda de araña.
Kraig Biocraft Laboratories (OTCQB: KBLB), 거미 실크 기술 분야의 선도 기업이 주요 동남아시아 실크 생산 지역에 위치한 두 곳의 신규 사육 센터로 생산 운영을 성공적으로 이전했다고 발표했습니다. 신규 시설은 자회사 Prodigy Silk가 운영하며, 2024년 초 첫 센터 개소 이후 역대 연간 생산량을 모두 합친 것보다 많은 생산을 이미 달성했습니다.
이 현대적 사육 센터들은 첨단 바이오테크놀로지와 지역의 오랜 누에 및 비단 생산 노하우, 유리한 기후와 인프라를 결합합니다. 회사는 원래의 파일럿 시설에서 장비 이전을 마무리하고 있으며, 2025년 8월 말까지 완료할 계획입니다. 이 전략적 이전은 Kraig Labs가 거미 실크 기술을 상용화하는 데 있어 중요한 확장 이정표입니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader dans la technologie de la soie d’araignée, a annoncé la réussite du transfert de ses opérations de production vers deux nouveaux centres d’élevage situés dans une grande région productrice de soie d’Asie du Sud-Est. Les nouvelles installations, exploitées par la filiale Prodigy Silk, ont déjà dépassé la production cumulée de toutes les années précédentes depuis l’ouverture du premier centre début 2024.
Ces centres modernes associent biotechnologie avancée, savoir-faire local en sériciculture, climat favorable et infrastructures. La société finalise le transfert des équipements depuis l’installation pilote d’origine, dont l’achèvement est prévu pour la fin août 2025. Ce mouvement stratégique constitue une étape majeure dans l’expansion commerciale de Kraig Labs pour la technologie de la soie d’araignée.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Vorreiter in der Spinnenseiden-Technologie, hat den erfolgreichen Umzug seiner Produktionsabläufe in zwei neue Aufzuchtzentren in einer bedeutenden Seidenregion Südostasiens angekündigt. Die neuen Anlagen, betrieben von der Tochtergesellschaft Prodigy Silk, haben seit der Eröffnung des ersten Zentrums Anfang 2024 bereits die kumulierte Produktion aller vorherigen Jahre übertroffen.
Die modernen Aufzuchtzentren vereinen fortschrittliche Biotechnologie mit der regionalen Serikultur-Expertise, dem günstigen Klima und der vorhandenen Infrastruktur. Das Unternehmen vervollständigt derzeit die Verlagerung der Ausrüstung aus der ursprünglichen Pilotanlage, die voraussichtlich bis Ende August 2025 abgeschlossen sein wird. Dieser strategische Schritt stellt einen wichtigen Meilenstein für Kraig Labs bei der Kommerzialisierung der Spinnenseiden-Technologie dar.
- Production output since early 2024 exceeds all previous years combined
- Strategic location in one of Asia's premier silk-producing regions provides natural advantages
- Modern facilities combine advanced biotechnology with regional expertise
- Successful consolidation of operations into purpose-built commercial facilities
- Complete dependence on new regional facilities may present geographic concentration risk
ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that its two recently established rearing centers, located in the heart of one of Asia's leading silk-producing regions, have now completely replaced the Company's original Prodigy Textiles pilot facility as the center of production.
Since opening the first of these two new rearing centers in early 2024, Kraig Labs has produced more recombinant spider silk than in all previous years of the Company's operations combined. These modern rearing centers provide an optimized production environment, combining advanced biotechnology with the region's unmatched sericulture expertise, favorable climate, and established infrastructure.
Kraig Labs has already begun transferring equipment from its original pilot facility to the new commercial production centers, with the process expected to be completed by the end of August. The commercial production facilities will now be operated by the Company’s wholly owned subsidiary, Prodigy Silk. The Prodigy Textile brand will remain active as a DBA of Kraig Labs.
"This marks a major milestone for Kraig Labs," said Jon Rice, COO of Kraig Labs. "By moving all of our resources into these purpose-built rearing centers, we are achieving a key expansion objective for 2025, operating in one of the world's leading silk production locations. With the region's natural advantages and our cutting-edge science, we are creating the strongest platform yet to deliver the promise of recombinant spider silk to global markets."
The establishment of these rearing centers is the culmination of nearly a decade of planning. With operations now anchored in one of the world's foremost silk-producing regions, Kraig Labs is taking a significant step forward in its mission to commercialize spider silk.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What are the new developments at Kraig Biocraft Laboratories (KBLB) in 2025?
Where are KBLB's new production facilities located?
How will the new rearing centers impact KBLB's production capacity?
Who will operate KBLB's new production facilities?
When will KBLB complete the transition to the new facilities?
